Open AccessSafety and efficacy of the simultaneous administration of udenafil and an α-blocker in men with erectile dysfunction concomitant with BPH/LUTS
Author(s) -
Byung Ha Chung,
J. Y. Lee,
S H Lee,
Sung Jin Yoo,
S W Lee,
Cheol Young Oh
Publication year - 2009
Publication title -
international journal of impotence research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.508
H-Index - 84
eISSN - 1476-5489
pISSN - 0955-9930
DOI - 10.1038/ijir.2009.2
Subject(s) - medicine , erectile dysfunction , lower urinary tract symptoms , concomitant , urology , international prostate symptom score , blood pressure , hyperplasia , benign prostatic hyperplasia (bph) , urinary retention , prostate , cancer
We evaluated the clinical efficacy and safety of administering udenafil (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)-pyrimidin-7-one) in patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). One hundred and twenty patients who had been undergoing stable alpha-blocker therapy for BPH were enrolled in this trial and they were administered 100 mg udenafil for 8 weeks. Changes in blood pressure (BP), heart rate (HR), the international prostatic symptom score (IPSS) and the international index of ED (IIEF-5) were evaluated every 4 weeks. At end point, there was no significant change in BP and HR, whereas the lower urinary tract symptoms (LUTS) and ED improved significantly compared with baseline (IPSS 14.3-11.5, IIEF-5 11.95-18.32, P<0.05). Most patients were tolerant to the treatment and there was no evidence of additional side effects related to coadministration. The coadministration of udenafil and an alpha-blocker in patients with comorbid BPH and ED was safe and gave significant improvements in both LUTS and ED.